273 related articles for article (PubMed ID: 23639324)
1. Has the time come for metronomics in low-income and middle-income countries?
André N; Banavali S; Snihur Y; Pasquier E
Lancet Oncol; 2013 May; 14(6):e239-48. PubMed ID: 23639324
[TBL] [Abstract][Full Text] [Related]
2. Metronomic Chemotherapy for Children in Low- and Middle-Income Countries: Survey of Current Practices and Opinions of Pediatric Oncologists.
Revon-Rivière G; Banavali S; Heississen L; Gomez Garcia W; Abdolkarimi B; Vaithilingum M; Li CK; Leung PC; Malik P; Pasquier E; Epelman S; Chantada G; André N
J Glob Oncol; 2019 Jul; 5():1-8. PubMed ID: 31260397
[TBL] [Abstract][Full Text] [Related]
3. Metronomics chemotherapy: time for computational decision support.
Barbolosi D; Ciccolini J; Meille C; Elharrar X; Faivre C; Lacarelle B; André N; Barlesi F
Cancer Chemother Pharmacol; 2014 Sep; 74(3):647-52. PubMed ID: 25082520
[TBL] [Abstract][Full Text] [Related]
4. Preliminary evaluation of children treated with metronomic chemotherapy and valproic acid in a low-income country: Metro-Mali-02.
Traore F; Togo B; Pasquier E; Dembélé A; André N
Indian J Cancer; 2013; 50(3):250-3. PubMed ID: 24061467
[TBL] [Abstract][Full Text] [Related]
5. Expansion of cancer care and control in countries of low and middle income: a call to action.
Farmer P; Frenk J; Knaul FM; Shulman LN; Alleyne G; Armstrong L; Atun R; Blayney D; Chen L; Feachem R; Gospodarowicz M; Gralow J; Gupta S; Langer A; Lob-Levyt J; Neal C; Mbewu A; Mired D; Piot P; Reddy KS; Sachs JD; Sarhan M; Seffrin JR
Lancet; 2010 Oct; 376(9747):1186-93. PubMed ID: 20709386
[TBL] [Abstract][Full Text] [Related]
6. Role of radiotherapy in cancer control in low-income and middle-income countries.
Barton MB; Frommer M; Shafiq J
Lancet Oncol; 2006 Jul; 7(7):584-95. PubMed ID: 16814210
[TBL] [Abstract][Full Text] [Related]
7. Metronomic chemotherapy: Back to the future!
André N; Padovani L; Verschuur A
Drug News Perspect; 2010 Mar; 23(2):143-51. PubMed ID: 20369080
[TBL] [Abstract][Full Text] [Related]
8. First-line systemic treatment of advanced stage non-small-cell lung cancer in Asia: consensus statement from the Asian Oncology Summit 2009.
Soo RA; Anderson BO; Cho BC; Yang CH; Liao M; Lim WT; Goldstraw P; Mok TS;
Lancet Oncol; 2009 Nov; 10(11):1102-10. PubMed ID: 19880064
[TBL] [Abstract][Full Text] [Related]
9. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
10. Increasing access to quality anticancer medicines in low- and middle-income countries: the experience of Uganda.
Osinde G; Niyonzima N; Mulema V; Kyambadde D; Mulumba Y; Obayo S; Anecho E; Watera S; Constance M; Kadhumbula S; Orem J
Future Oncol; 2021 Jul; 17(21):2735-2745. PubMed ID: 33855863
[TBL] [Abstract][Full Text] [Related]
11. [Risk sharing methods in middle income countries].
Inotai A; Kaló Z
Acta Pharm Hung; 2012; 82(1):43-52. PubMed ID: 22570986
[TBL] [Abstract][Full Text] [Related]
12. Drugs are scarce as mix of programs aims to ease access.
Brower V
J Natl Cancer Inst; 2009 Oct; 101(19):1304-6. PubMed ID: 19755680
[No Abstract] [Full Text] [Related]
13. Health policy: Putting a price on cancer.
Sullivan R; Aggarwal A
Nat Rev Clin Oncol; 2016 Mar; 13(3):137-8. PubMed ID: 26856742
[No Abstract] [Full Text] [Related]
14. Achievements and challenges in the use of metronomics for the treatment of breast cancer.
Scharovsky OG; Rico MJ; Mainetti LE; Perroud HA; Rozados VR
Biochem Pharmacol; 2020 May; 175():113909. PubMed ID: 32173366
[TBL] [Abstract][Full Text] [Related]
15. Access to Cytotoxic Medicines by Children With Cancer: A Focus on Low and Middle Income Countries.
Barr R; Robertson J
Pediatr Blood Cancer; 2016 Feb; 63(2):287-91. PubMed ID: 26375626
[TBL] [Abstract][Full Text] [Related]
16. Regulatory and logistical issues influencing access to antineoplastic and supportive care medications for children with cancer in developing countries.
Wiernikowski JT; MacLeod S;
Pediatr Blood Cancer; 2014 Aug; 61(8):1513-7. PubMed ID: 24753431
[TBL] [Abstract][Full Text] [Related]
17. [Metronomic chemotherapy in pediatric oncology: hype or hope?].
André N; Pasquier E; Verschuur A; Sterba J; Gentet JC; Rössler J
Arch Pediatr; 2009 Aug; 16(8):1158-65. PubMed ID: 19446445
[TBL] [Abstract][Full Text] [Related]
18. Expanding global access to radiotherapy.
Atun R; Jaffray DA; Barton MB; Bray F; Baumann M; Vikram B; Hanna TP; Knaul FM; Lievens Y; Lui TY; Milosevic M; O'Sullivan B; Rodin DL; Rosenblatt E; Van Dyk J; Yap ML; Zubizarreta E; Gospodarowicz M
Lancet Oncol; 2015 Sep; 16(10):1153-86. PubMed ID: 26419354
[TBL] [Abstract][Full Text] [Related]
19. Essential medicines for pediatric oncology in developing countries.
Mehta PS; Wiernikowski JT; Petrilli JA; Barr RD;
Pediatr Blood Cancer; 2013 May; 60(5):889-91. PubMed ID: 23450774
[TBL] [Abstract][Full Text] [Related]
20. Controlling multidrug-resistant tuberculosis and access to expensive drugs: a rational framework.
Pablos-Mendez A; Gowda DK; Frieden TR
Bull World Health Organ; 2002; 80(6):489-95; discussion 495-500. PubMed ID: 12132008
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
